---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-109158"
form_type: "8-K"
ticker: "PASG"
cik: "0001787297"
company_name: "Passage BIO, Inc."
filed_at: "2025-11-10T23:59:59+00:00"
generated_at: "2026-05-16T22:32:02.592599+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Passage Bio Q3 net loss $7.7M; cash runway into 1Q 2027; FTD trial enrollment ongoing

## Summary
- Cash and marketable securities $52.8M as of Sep 30, 2025; expected to fund operations into 1Q 2027.
- Net loss narrowed to $7.7M ($2.44 per share) vs $19.3M ($6.15) in Q3 2024; R&D and G&A expenses declined.
- Enrolling Cohort 3 (FTD-GRN) and Cohort 4 (FTD-C9orf72) in upliFT-D study; interim data expected in 1H 2026.
- Aligned with FDA on analytical comparability plan for suspension-based PBFT02 manufacturing process.
- On track for FDA feedback on FTD-GRN registrational trial design in 1H 2026.

## SEC filing metadata
- accession: 0001104659-25-109158
- form_type: 8-K
- ticker: PASG
- cik: 0001787297
- company_name: Passage BIO, Inc.
- filed_at: 2025-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787297/000110465925109158/0001104659-25-109158-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787297/000110465925109158/pasg-20251110x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-109158
- JSON: https://secwatch.observer/filing/0001104659-25-109158.json
- Plain text: https://secwatch.observer/filing/0001104659-25-109158.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.